Powerful Results
In CARTITUDE-4
![Expand Icon](/_next/static/media/expand-plus.8efeb45f.png)
CARVYKTI® SIGNIFICANTLY PROLONGED Progression-Free Survival (PRIMARY ENDPOINT) vs STANDARD THERAPY (DPd OR PVd)*1
![61% (n=208) MRD-5 negativity cilta-cel vs 16% (n=211) MRD-5 negativity SoC (PVd or DPd)](/_next/static/media/cartitude-pfs-itt-chart.160040f2.png)
PFS SUBGROUP ANALYSIS
PFS SUBGROUP ANALYSIS
Percentages rounded to nearest whole number.
CI=confidence interval; DOR=duration of response; DPd=daratumumab, pomalidomide, and dexamethasone; HR=hazard ratio; ITT=intent to treat; mPFS=median progression-free survival; MRD=minimal residual disease; ORR=overall response rate; PVd=pomalidomide, bortezomib, and dexamethasone.
*Median follow-up was 15.9 months in the Intent-to-Treat Analysis Set.